文献速递淋巴瘤

匹莫齐特通过溶酶体破坏与STAT抑制双重作用诱导CLL细胞凋亡

Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL).
PubMed 文献 · Blood Adv · 2026-01-01

本研究在慢性淋巴细胞白血病(CLL)中鉴定FDA批准的抗精神病药匹莫齐特为双功能剂:诱导溶酶体膜通透化经活性氧途径促凋亡,并抑制STAT5磷酸化、降低IL-4诱导的MCL-1表达,且在复发患者CLL细胞中仍有效,与venetoclax协同克服微环境介导耐药。

要点

  • 匹莫齐特通过溶酶体膜通透化及活性氧产生诱导CLL细胞凋亡。
  • 匹莫齐特抑制STAT5磷酸化并降低IL-4诱导的MCL-1表达。
  • 匹莫齐特与venetoclax协同,在IL-4/CD40L信号后仍诱导凋亡。

核心结论

  • 匹莫齐特通过破坏溶酶体功能与抑制STAT信号双重机制诱导CLL细胞凋亡,并与venetoclax协同克服微环境介导的耐药。

研究设计与样本

  • 本研究为体外实验研究,使用CLL患者来源细胞,未报告样本量。

主要发现

  • 匹莫齐特诱导溶酶体膜通透化,通过增加活性氧产生导致CLL细胞凋亡。
  • 匹莫齐特抑制STAT5磷酸化,降低IL-4诱导的MCL-1表达,并阻止IL-4/CD40L介导的凋亡抑制。
  • 匹莫齐特对治疗后复发患者的CLL细胞仍有效诱导凋亡。
  • 匹莫齐特与venetoclax协同,在IL-4/CD40L信号存在下仍诱导CLL细胞凋亡。

临床怎么用

  • 匹莫齐特作为已获批药物,可能为CLL治疗提供新选择,尤其针对微环境介导的venetoclax耐药。

局限性

  • 研究为体外实验,缺乏临床体内数据验证匹莫齐特在CLL患者中的疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL) progression and therapeutic resistance are driven in large part by protective signals from the tumor microenvironment (TME), which includes T-cell-derived cytokines such as interleukin-4 (IL-4) that promote survival via signal transducer and activator of transcription (STAT) signaling and upregulation of antiapoptotic proteins such as the B-cell lymphoma 2 (BCL-2) family member myeloid cell leukemia 1 (MCL-1). Although the BCL-2 inhibitor venetoclax has demonstrated significant clinical efficacy, microenvironment-induced resistance, particularly by MCL-1 upregulation, remains a major limitation. Here, we identify the US Food and Drug Administration-approved antipsychotic drug pimozide as a dual-function agent that induces lysosome membrane permeabilization, leading to apoptosis in CLL cells through increased reactive oxygen species production. In addition, pimozide inhibited STAT5 phosphorylation, reduced IL-4-induced MCL-1 expression, and prevented IL-4/CD40L-mediated inhibition of apoptosis. Importantly, pimozide remains effective in inducing apoptosis in CLL cells from patients who have relapsed after therapy. Pimozide also synergizes with venetoclax to induce apoptosis in CLL cells even after IL-4/CD40L signaling. This suggests that dual targeting of lysosomal function and STAT signaling represents a promising therapeutic approach to improve venetoclax efficacy and overcome TME-mediated drug resistance in CLL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Manivannan MS, Yang X, Patel N, et al. Dual action of pimozide through lysosome disruption and inhibition of STATs induces apoptosis in chronic lymphocytic leukemia (CLL). Blood Adv. 2026. PMID: 42085602. doi:10.1182/bloodadvances.2025018362

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。